<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Infect Dis Obstet Gynecol</journal-id><journal-title>Infectious Diseases in Obstetrics and Gynecology</journal-title><issn pub-type="ppub">1064-7449</issn><issn pub-type="epub">1098-0997</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">18476152</article-id><article-id pub-id-type="pmc">2364549</article-id>
		<article-id pub-id-type="pii">S1064744997000483</article-id>
		<article-id pub-id-type="doi">10.1155/S1064744997000483</article-id>
	<article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Double-Blind, Multicenter, Prospective Randomized Study of Trospectomycin Vs. Clindamycin, Both With Aztreonam, in Non-Community Acquired Obstetric and Gynecologic Infections</article-title></title-group><contrib-group>
		<contrib contrib-type="author" corresp="yes"><name><surname>Chatwani</surname><given-names>Ashwin</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff7">7</xref></contrib>
		<contrib contrib-type="author"><name><surname>Martens</surname><given-names>Mark</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib>
		<contrib contrib-type="author"><name><surname>Blanco</surname><given-names>Jorge</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib>
		<contrib contrib-type="author"><name><surname>Gall</surname><given-names>Stanley</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib>
		<contrib contrib-type="author"><name><surname>Przybylko</surname><given-names>Kira</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib>
		<contrib contrib-type="author"><name><surname>Wajszczuk</surname><given-names>Charles P.</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib>
		<contrib contrib-type="author"><name><surname>Nickens</surname><given-names>Dana</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib>
	</contrib-group>
		<aff id="aff1"><label>1</label>
			<addr-line>Department of Obstetrics and Gynecology</addr-line>
			<addr-line>Temple University School of Medicine</addr-line>
			<addr-line>Philadelphia</addr-line>
			<addr-line>PA</addr-line>
			<country>USA</country>
		</aff>
		<aff id="aff2"><label>2</label>
			<addr-line>Department of Obstetrics and Gynecology</addr-line>
			<addr-line> Hennepin County Medical Center</addr-line>
			<addr-line>Minneapolis</addr-line>
			<addr-line>MN</addr-line>
			<country>USA</country>
		</aff>
		<aff id="aff3"><label>3</label>
			<addr-line>Department of Obstetrics and Gynecology</addr-line>
			<addr-line>LBJ Hospital</addr-line>
			<addr-line>Houston</addr-line>
			<addr-line>TX</addr-line>
			<country>USA</country>
		</aff>
		<aff id="aff4"><label>4</label>
			<addr-line>Department of Obstetrics and Gynecology</addr-line>
			<addr-line> University of Louisville</addr-line>
			<addr-line>Louisville</addr-line>
			<addr-line>KY</addr-line>
			<country>USA</country>
		</aff>
		<aff id="aff5"><label>5</label>
			<addr-line>Section of Antimicrobial Research</addr-line>
			<addr-line>Pharmacia &#x00026; Upjohn, Inc.</addr-line>
			<addr-line>Kalamazoo</addr-line>
			<addr-line>MI</addr-line>
			<country>USA</country>
		</aff>
		<aff id="aff6"><label>6</label>
			<addr-line>Section of Medical Statistics</addr-line>
			<addr-line>Pharmacia &#x00026; Upjohn, Inc.</addr-line>
			<addr-line>Kalamazoo</addr-line>
			<addr-line>MI</addr-line>
			<country>USA</country>
		</aff>
		<aff id="aff7"><label>7</label>
			<addr-line>Department of Obstetrics and Gynecology</addr-line>
			<addr-line>RS, 3401 N. Broad Street, 70PB</addr-line>
			<addr-line>Philadelphia</addr-line>
			<addr-line>PA</addr-line>
			<addr-line>19140</addr-line>
			<country>USA</country>
		</aff>
	<pub-date pub-type="ppub"><year>1997</year></pub-date><volume>5</volume><issue>4</issue><fpage>280</fpage><lpage>285</lpage><history><date date-type="received"><day>13</day><month>5</month><year>1997</year></date><date date-type="accepted"><day>29</day><month>8</month><year>1997</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 1997 Hindawi Publishing Corporation.</copyright-statement><copyright-year>1997</copyright-year><copyright-holder>Hindawi Publishing Corporation</copyright-holder><license license-type="open-access" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://creativecommons.org/licenses/by/"><p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract>
		<p>
			<italic>Objective:</italic> The purpose of this study was to compare the clinical efficacy and safety of trospectomycin sulfate with that of clindamycin phosphate, both with aztreonam, for the treatment of obstetric and gynecologic infections.</p>
		<p>
			<italic>Methods:</italic> In a double-blind, multicenter, prospective randomized study, 579 patients with either endometritis following cesarean delivery or pelvic cellulitis following hysterectomy were enrolled and received medication. Administered was either trospectomycin sulfate 500 mg IV every 8 h or clindamycin phosphate 900 mg IV every 8 h in a 1:1 randomization ratio. Both groups of patients received aztreonam 1 g IV every 8 h. The patients were followed for clinical responses and side effects.</p>
		<p>
			<italic>Results:</italic> The cure rate for the trospectomycin sulfate arm was 91.8% and for clindamycin phosphate arm it was 88.4% (<italic>P</italic> = 0.218). The adverse events were similar in both groups.</p>
		<p>
			<italic>Conclusions:</italic> Trospectomycin was as effective as clindamycin, when both were combined with aztreonam, in treatment of obstetric and gynecologic infections.</p>
	</abstract></article-meta></front></article>


